A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD
Latest Information Update: 21 Mar 2025
At a glance
- Drugs ALN PNP (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Regeneron Pharmaceuticals
- 18 Mar 2025 Planned End Date changed from 10 Sep 2025 to 18 Oct 2025.
- 18 Mar 2025 Planned primary completion date changed from 10 Sep 2025 to 18 Oct 2025.
- 18 Mar 2025 Status changed from recruiting to active, no longer recruiting.